News About: Pharm. Industry
Listed pharmaceutical companies significantly raise exports in first half
While pharmaceutical companies are following the ‘drive’ policy in exportation, their exports and foreign sales were largely increased in the first half of the year. In particular, the growth rate of KOSDAQ listed pha...
Listed pharmaceuticals earn KRW 75 from selling products of KRW 1,000
Listed pharmaceutical companies were analyzed to generate KRW 75 by selling manufactured goods(including products) of KRW 1,000 in the 1st half of the year.
According to the Yakup Shinmoon’s(www.yakup.com) analysis ...
SRLRC rules unfair dismissal of employees to Sanofi
Labor-management conflicts continue in multinational pharmaceutical companies. This time, it is a French pharmaceutical company, Sanofi.
The Seoul Regional Labor Relation Commission(SRLRC) ruled a decision of unfair ...
Listed pharmaceuticals’ sales & management expense ratio continues to decrease
Listed pharmaceutical companies have actively working on cutting their sales & management expenses to increase profitability.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of the 2016 first half’s ...
Handok introduces Australia’s top nasal spray in Korea, expanding OTC businessThe Handok’s OTC business has started to bear fruits. Handok which acquired an arthritis treatment ‘Ketotop’ through acquiring Pacific Pharmaceuticals succeeded in acquiring the...
|
Multinational pharmaceuticals surprised by Novartis crisis, “Lawful academic supports should not be restricted”
As the prosecution’s Novartis rebate investigation which was conducted from last February was finalized with indictment of 34 people including its current and former executives without detention, other multinational p...
Very ‘decent’ sales performances of listed pharmaceutical companies in first half
Listed pharmaceutical companies’ sales performances were evaluated as decent in the first half of the year.
Their sales growth rate was above 10%, their profit growth rate reached 30%, and their net profits were also...
Novartis’ incident cause anxiety among multinational companies
As a investigation result of rebates on Novartis Korea which records the top second sales among other multinational pharmaceutical companies branched in Korea, attention has bee focused on multinational pharmaceutical...
Sad story of the first generic independent from ‘authorized’ status
The first domestic generic which got independent from an authorized generic came out. However, a criticism has slowly been spread that contracts that are more advantageous to pharmaceutical companies owning original p...
Celltrion’s Remsima & Samsung’s SB5 about to be launched in US and Europe
Celltrion(CEO Jung-jin Seo) and Samsung Bioepis(CEO Han-seung Ko) got a step closer to pioneering the U.S. and European markets.
According to the industry concerned, a U.S. patent suit on a Celltrion’s Remicade biosi...
